{"title":"Clinical observation and immune effect of high-intensity focused ultrasound (HIFU) treatment on patients with colorectal cancer liver metastasis.","authors":"Shasha Wang, Zhanmeng Zhang, Libin Sun, Jiashuo Li, Haowen Liu, Xiaojuan Huang, Jinfeng Cui, Chuyang Zhu, Shibo Wang, Wenzhi Chen, Wensheng Qiu","doi":"10.1080/02656736.2025.2519344","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the clinical and immune effects of high-intensity focused ultrasound (HIFU) on liver metastases from colorectal cancer (CRC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 64 CRC patients with liver metastases treated with HIFU at Qingdao University's HIFU Cancer Center. Variables such as sex, age, ECOG status, tumor location, KRAS mutation status, HBV infection, number and size of liver metastases, and previous systemic treatments were analyzed. The impact of systemic treatment lines on progression-free survival (PFS) and overall survival (OS) was assessed. A subgroup of 24 patients receiving HIFU combined with first-line therapy was matched with 21 patients receiving chemotherapy alone for comparison.</p><p><strong>Results: </strong>Sixty-four patients underwent 69 HIFU treatments. Median survival was 52 months, with 1-year survival at 100%, 2-year survival at 93.3% and 3-year survival at 72%. The number of metastases treated with HIFU and systemic treatment lines significantly influenced survival (<i>p</i> < 0.05). Post-treatment serum IL-6 levels decreased significantly (<i>p</i> < 0.001). OS was significantly better in the HIFU + chemotherapy group compared to chemotherapy-only (<i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>HIFU significantly improves OS in CRC liver metastasis patients and reduces serum IL-6 levels, suggesting enhanced immune responses.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519344"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/02656736.2025.2519344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study evaluates the clinical and immune effects of high-intensity focused ultrasound (HIFU) on liver metastases from colorectal cancer (CRC).
Methods: A retrospective analysis was conducted on 64 CRC patients with liver metastases treated with HIFU at Qingdao University's HIFU Cancer Center. Variables such as sex, age, ECOG status, tumor location, KRAS mutation status, HBV infection, number and size of liver metastases, and previous systemic treatments were analyzed. The impact of systemic treatment lines on progression-free survival (PFS) and overall survival (OS) was assessed. A subgroup of 24 patients receiving HIFU combined with first-line therapy was matched with 21 patients receiving chemotherapy alone for comparison.
Results: Sixty-four patients underwent 69 HIFU treatments. Median survival was 52 months, with 1-year survival at 100%, 2-year survival at 93.3% and 3-year survival at 72%. The number of metastases treated with HIFU and systemic treatment lines significantly influenced survival (p < 0.05). Post-treatment serum IL-6 levels decreased significantly (p < 0.001). OS was significantly better in the HIFU + chemotherapy group compared to chemotherapy-only (p < 0.0001).
Conclusion: HIFU significantly improves OS in CRC liver metastasis patients and reduces serum IL-6 levels, suggesting enhanced immune responses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
